Hospira HSP

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
    1. Hospira wins U.K. patent suit

      Headlines

      Thu, 10 Apr 2014

      OTCQX:RHHBY -0.7% ) 115 and 455 Herceptin patents are invalid paving the way for Hospira ( HSP -3.5% ) to market a biosimilar version in Britain. Hospira wants to sell its offering of trastuzumab after Herceptin's core patent expires on

    2. UPDATE 1- Hospira wins UK case to overturn patents on Roche drug Herceptin

      Headlines

      Thu, 10 Apr 2014

      * Roche considering its next steps (Adds Roche and Hospira comment, patent details)

    3. Hospira wins UK case to overturn patents on Roche drug Herceptin

      Headlines

      Thu, 10 Apr 2014

      LONDON, April 10 (Reuters) - Hospira has successfully overturned two patents on Roche's top-selling breast cancer drug Herceptin in Britain, clearing the way for it to launch a cheaper copycat version in the country.

    4. Critical Shortage Of Injectables Create Opportunity For Drugmakers

      Headlines

      Wed, 9 Apr 2014

      intravenously to treat hypertension and assorted heart conditions, is one of those drugs. Last year, two manufacturers -- Hospira ( HSP ) and American Regent, owned by Luitpold Pharmaceuticals -- stopped selling injectable nitroglycerin, making Baxter

    5. Oakmark Equity and Income Fund Letter to Shareholders

      Headlines

      Tue, 8 Apr 2014

      establish a meaningful position. Hospira was a longtime holding of the Fund ..... Laboratories, which spun-off Hospira ten years ago. Over ..... Crane Co. 0%, Encana Corp. 0%, Hospira , Inc . 0%, Abbott Laboratories 0

    6. No infringement on Angiomax

      Headlines

      Tue, 1 Apr 2014

      Shares of The Medicines Company ( MDCO -14.7% ) drop after a Delaware court finds that Hospira 's ( HSP +1.6% ) aNDA for a generic bivalirudin does not infringe on Angiomax patents '727 and '343. The court has yet

    7. Hospira agrees to $60 mln settlement over quality control problems

      Headlines

      Thu, 27 Mar 2014

      NEW YORK, March 27 (Reuters) - Hospira Inc has agreed to pay $60 million to resolve a class action lawsuit accusing the drug maker of misleading investors about quality control problems that undermined an initiative to improve the company's margins and operations.

    8. Cramer's Lightning Round - Frontier Communications Is Going To Make It (3/26/14)

      Headlines

      Thu, 27 Mar 2014

      has a lower yield (than Inland). I think it is better run." Lockheed Martin ( LMT ): "Great buyback, great dividend, great management. That is for me." Hospira ( HSP ): "This is a very good company with real Complete Story »

    9. New Morningstar Analyst Report for Amgen Inc

      Stock Reports

      Tue, 18 Mar 2014

      Neupogen in the U.S. in 2014 (including a branded neutropenia product from Teva and biosimilar Epogen competition from Hospira ). However, Teva's setbacks with its long-acting neutropenia products have caused us to increase our U.S. Neulasta

    10. New Morningstar Analyst Report for Cubist Pharmaceuticals, Inc.

      Stock Reports

      Mon, 27 Jan 2014

      Cubicin is facing a patent challenge from Hospira .If Cubist's CB-315/Surotomycin ..... news was a big win for Cubist, but Hospira has now also challenged the drug's patent. There is a risk that Hospira could prevail in litigation, and Cubicin

    « Prev12345Next »
    Content Partners